Table 4 Active, recruiting, and completed phase I to III clinical trials for NB

ALK

Crizotinib

NCT00939770

I/II

None

NCT03126916

III

Carboplatin / Cisplatin / Cyclophosphamide / Dinutuximab / Doxorubicin /

Etoposide / Isotretinoin / Thiotepa / Topotecan / Radiation Therapy

NCT01606878

I

Cyclophosphamide / Topotecan or Doxorubicin / Vincristine

NCT03194893

III

None

NCT01121588

I

None

NTR5584

I

Temsirolimus

Lorlatinib

NCT03107988

I

Cyclophosphamide / Topotecan

Ceritinib

NCT02559778

II

DFMO

NCT02780128

I

Ribociclib (CDK4/CDK6 inhibitor)

NCT01742286

I

None

Entrectinib

NCT02650401^a

I/II

None

Ensartinib

NCT03155620

II

None

NCT03213652

II

None

Alectinib

NCT03194893

III

None

FGFR

Erdafitinib

NCT03210714

II

None

NCT03155620

II

None

RAS

Tipifarnib

NCT03155620

II

None

NCT04284774

II

None

BRAF

Dabrafenib

NCT02124772

I/II

Trametinib

Sorafenib

NCT02559778

II

DFMO

NCT01518413

I

Irinotecan

NCT01683149

I

Topotecan

NCT00665990

I

Bevacizumab / Cyclophosphamide

NCT02298348

I

Topotecan / Cyclophosphamide

Vemurafenib

NCT03220035

II

None

NCT01596140

I

Everolimus / Temsirolimus

NCT03155620

II

None

TAK-580^b

NCT03429803

I

None

MEK 1/2

Trametinib

NCT03434262

I

Ribociclib

NCT02124772

I/II

Dabrafenib

Selumetinib

NCT03155620

II

None

NCT03213691

II

None

Cobimetinib

NCT02639546

I/II

None

Binimetinib

NCT02285439

I/II

None

ERK 1/2

Ulixertinib

NCT03698994

II

None

NCT03155620

II

None